Eyebright Medical Technology (Beijing) Future Growth
Future criteria checks 5/6
Eyebright Medical Technology (Beijing) is forecast to grow earnings and revenue by 30.5% and 28.5% per annum respectively. EPS is expected to grow by 30.9% per annum. Return on equity is forecast to be 18.1% in 3 years.
Key information
30.5%
Earnings growth rate
30.9%
EPS growth rate
| Medical Equipment earnings growth | 26.4% |
| Revenue growth rate | 28.5% |
| Future return on equity | 18.1% |
| Analyst coverage | Low |
| Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,539 | 711 | N/A | 647 | 4 |
| 12/31/2025 | 1,959 | 539 | N/A | 529 | 4 |
| 12/31/2024 | 1,471 | 388 | N/A | 359 | 1 |
| 9/30/2024 | 1,358 | 370 | -173 | 299 | N/A |
| 6/30/2024 | 1,230 | 349 | -225 | 255 | N/A |
| 3/31/2024 | 1,072 | 328 | -208 | 239 | N/A |
| 12/31/2023 | 951 | 304 | -158 | 213 | N/A |
| 9/30/2023 | 806 | 287 | -79 | 175 | N/A |
| 6/30/2023 | 713 | 272 | -76 | 200 | N/A |
| 3/31/2023 | 638 | 252 | -25 | 236 | N/A |
| 12/31/2022 | 579 | 233 | -21 | 250 | N/A |
| 9/30/2022 | 549 | 229 | -51 | 280 | N/A |
| 6/30/2022 | 500 | 203 | -58 | 255 | N/A |
| 3/31/2022 | 480 | 194 | -71 | 230 | N/A |
| 12/31/2021 | 433 | 171 | -92 | 219 | N/A |
| 9/30/2021 | 416 | 168 | -10 | 217 | N/A |
| 6/30/2021 | 376 | 150 | 17 | 201 | N/A |
| 3/31/2021 | 331 | 129 | -19 | 160 | N/A |
| 12/31/2020 | 273 | 97 | 5 | 123 | N/A |
| 9/30/2020 | 237 | 86 | -9 | 83 | N/A |
| 6/30/2020 | 204 | 68 | -23 | 43 | N/A |
| 3/31/2020 | 178 | 53 | -93 | 44 | N/A |
| 12/31/2019 | 195 | 67 | -91 | 50 | N/A |
| 12/31/2018 | 127 | 20 | -40 | 32 | N/A |
| 12/31/2017 | 75 | -4 | N/A | 4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688050's forecast earnings growth (30.5% per year) is above the savings rate (2.8%).
Earnings vs Market: 688050's earnings (30.5% per year) are forecast to grow faster than the CN market (26.1% per year).
High Growth Earnings: 688050's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688050's revenue (28.5% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688050's revenue (28.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688050's Return on Equity is forecast to be low in 3 years time (18.1%).